menu
    • menu
    [{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Factor XI","graph1":"Hematology","graph2":"Undisclosed","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Anthos Therapeutics \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Anthos Therapeutics \/ Anthos Therapeutics"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Abelacimab","moa":"Factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Itreas","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Itreas","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Itreas"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":3.0800000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":3.0800000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Anthos Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Novartis Pharmaceuticals Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Anthos Therapeutics

    Menu

    Anthos Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $3,075.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront

                            Details : Through the acquisition, Novartis will strengthen its cardiovascular portfolio with Anthos' MAA868 (abelacimab), a potential monoclonal antibody for the treatment of atrial fibrillation.

                            Product Name : MAA868

                            Product Type : Antibody

                            Upfront Cash : $925.0 million

                            February 11, 2025

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $3,075.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anthos Highlights Abelacimab’s Bleeding Reduction Over Rivaroxaban in AZALEA-TIMI 71

                            Details : MAA868 (abelacimab) is a highly selective, mAb designed to induce hemostasis-sparing anticoagulation through Factor XI inhibition, in patients with Atrial Fibrillation with high risk of stroke.

                            Product Name : MAA868

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 16, 2024

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anthos Therapeutics Shares New Data on Abelacimab's Low Bleeding Risk

                            Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.

                            Product Name : MAA868

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 02, 2024

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anthos Announces 84% Transition to Abelacimab in AZALEA-TIMI 71 Study for AFib at a Stroke

                            Details : MAA868 (abelacimab) is a highly selective, monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition, in patients with Atrial Fibrillation.

                            Product Name : MAA868

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 06, 2024

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reductio...

                            Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.

                            Product Name : MAA868

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 13, 2023

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Memphis Seniors with a History of Atrial Fibrillation Joining New Research Study

                            Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.

                            Product Name : MAA868

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 20, 2023

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelmin...

                            Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition, which is investigated for patients with atrial fibrillation at moderate-to-high risk ...

                            Product Name : MAA868

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 18, 2023

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Itreas

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics' Dual-Acting Factor ...

                            Details : MAA868 (abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.

                            Product Name : MAA868

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 08, 2023

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Itreas

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation D...

                            Details : MAA868 (Abelacimab) is a highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition. It has received FDA Fast-Track Designations for the prevention systemic embolism with...

                            Product Name : MAA868

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 03, 2023

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Anthos Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab

                            Details : MAA868 (abelacimab) is dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity, targets active domain of Factor XI, demonstrating dual inhibitory activity against both Factor XI and its activ...

                            Product Name : MAA868

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 25, 2022

                            Lead Product(s) : Abelacimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth